Sanofi bets big on Alzheimer’s drug with bold biotech buyout


Author: Biopharma Diver
Share

Sanofi is doubling down on neuroscience with a $470 million acquisition of Vigil Neuroscience, securing full rights to an early-stage Alzheimer’s drug targeting the immune-linked protein TREM2. This bold move follows a 2023 investment that gave Sanofi a front-row seat to Vigil’s small molecule platform and reflects the company’s long-term commitment to neurology, even as the segment currently lags behind its oncology and immunology offerings.

VG-3927, the lead candidate, has completed Phase 1 trials and aligns with Sanofi’s strategy of using immunology to tackle neurodegeneration. While rivals have struggled with TREM2-based drugs, Sanofi is signalling confidence in the target’s potential. The acquisition excludes Vigil’s other pipeline drug, which returns to Amgen.

This deal underscores Sanofi’s appetite for high-risk, high-reward assets that deepen its neuroscience pipeline while staying true to its immunology-first approach.

Read the full breakdown of Sanofi’s neuroscience pivot. 



Discover What's Happening

Pharma Industry Awards 2025

November 20th, 2025

Dublin Royal Convention Centre

Pharma Industry Awards UK 2025

September 10th, 2025

Park Plaza London Riverbank

Life Sciences Industry Awards 2025

June 5th, 2025

Crowne Plaza Hotel, Santry

Women in Pharma Awards 2025

May 22nd, 2025

Crowne Plaza Hotel, Santry

Business Sustainability Updates, Straight to Your Inbox

Explore our newsletters

Join our Newsletter to receive the latest industry trends, expert tips, and exclusive insights delivered straight to your inbox!